UROVANT SCIENCES INC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$9.2M
Doctors Paid
9,422
Transactions
38,771
2022 Total
$7.2M
Payment Breakdown by Category
Research$7.0M (75.6%)
Food & Beverage$767,926 (8.3%)
Consulting$305,443 (3.3%)
Travel$232,117 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.0M | 1,070 | 75.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $924,862 | 502 | 10.0% |
| Food and Beverage | $767,926 | 35,981 | 8.3% |
| Consulting Fee | $305,443 | 158 | 3.3% |
| Travel and Lodging | $232,117 | 963 | 2.5% |
| Space rental or facility fees (teaching hospital only) | $8,000 | 2 | 0.1% |
| Education | $3,430 | 90 | 0.0% |
| Honoraria | $2,448 | 5 | 0.0% |
Payments by Type
Research
$7.0M
1,070 transactions
General
$2.2M
37,701 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | $4.6M | 0 | 455 |
| Composur, A Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder | $700,844 | 0 | 251 |
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | $490,024 | 0 | 110 |
| An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence | $468,080 | 0 | 225 |
| AnOpen-Label, Randomized, Crossover, Single Dose Study to Assess thePharmacokinetics and Safety of Vibegron TabletandGranuleFormulations | $426,237 | 0 | 13 |
| An open-label, randomized, croosover, single dose study to assess the pharmacokinetics and saftey of vibegron tablet and granule formulations | $230,828 | 0 | 11 |
| A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC) | $7,500 | 0 | 1 |
| A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) (Empowur) | $5,000 | 0 | 1 |
| Composur | $1,976 | 0 | 3 |
Payments by Medical Specialty
Top Paid Doctors — Page 9
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Dr. Jimena Blandon, M.d, M.D | Internal Medicine | Miami, FL | $390.00 | $0 |
| Dr. Laura Martinez, Md, MD | Urology | Sugar Land, TX | $389.59 | $0 |
| Ms. Kathryn Villarreal, P.a, P.A | Physician Assistant | Fresno, CA | $387.86 | $0 |
| Beatrice Muma, Np, NP | Nurse Practitioner | Hanover, MD | $387.62 | $0 |
| Denia Caneta | Family | Fresno, CA | $387.22 | $0 |
| Robert James, M.d, M.D | Urology | Santa Rosa, CA | $386.41 | $0 |
| Jessica Nelson, Pa-C, PA-C | Medical | Dallas, TX | $384.08 | $0 |
| Ricardo Palmerola, M.d, M.D | Urogynecology and Reconstructive Pelvic Surgery | Coral Gables, FL | $383.22 | $0 |
| Dr. Rebecca Lavelle, M.d, M.D | Urology | Maryville, TN | $381.91 | $0 |
| Marc Lavine, Md, MD | Urology | Philadelphia, PA | $381.32 | $0 |
| Jana Zeitvogel, Crnp, CRNP | Family | Pell City, AL | $381.22 | $0 |
| Dr. Lei Chu, M.d, M.D | Urology | Houston, TX | $380.52 | $0 |
| Christina Hicks, Ms, Aprn, Whnp-Bc,, MS, APRN, WHNP-BC, | Women's Health | Dallas, TX | $380.41 | $0 |
| Dr. Mark Smith, M.d, M.D | Specialist | Sheffield, AL | $379.72 | $0 |
| Sasha Wainstein | Urology | Jackson Heights, NY | $377.08 | $0 |
| Mr. Anthony Tillman, Pa, PA | Physician Assistant | Maryville, TN | $375.68 | $0 |
| Icela Williams, Np, NP | Gerontology | Lafayette, LA | $375.00 | $0 |
| Michael Albright | Medical | Goldsboro, NC | $374.10 | $0 |
| Rachel Bowers, Pa, PA | Surgical | Las Vegas, NV | $373.58 | $0 |
| Sandip Vasavada, Md, MD | Urology | Cleveland, OH | $372.09 | $0 |
| Sarah Bartlett | Adult Health | Cary, NC | $370.23 | $0 |
| Stacy Slade, Pa-C, PA-C | Physician Assistant | Las Vegas, NV | $370.11 | $0 |
| Mrs. Diane Schmidt, Crnp, CRNP | Nurse Practitioner | Towson, MD | $369.66 | $0 |
| Courtney Falls, Crnp, CRNP | Women's Health | Huntsville, AL | $369.40 | $0 |
| William Porter, Md, MD | Urogynecology and Reconstructive Pelvic Surgery | Charlotte, NC | $369.17 | $0 |
About UROVANT SCIENCES INC
UROVANT SCIENCES INC has made $9.2M in payments to 9,422 healthcare providers, recorded across 38,771 transactions in the CMS Open Payments database. In 2022, the company paid $7.2M. The top product by payment volume is GEMTESA ($8.7M).
Payments were distributed across 123 medical specialties. The top specialty by payment amount is Urology ($899,546 to 3,135 doctors).
Payment categories include: Food & Beverage ($767,926), Consulting ($305,443), Research ($7.0M), Travel & Lodging ($232,117).
UROVANT SCIENCES INC is associated with 1 products in the CMS Open Payments database.